Biomea Fusion Inc(BMEA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.5 | Insider Own | 6.76% | Shs Outstand | 72.5M | Perf Week | -12.67% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | -4.28% | Insider Trans | - | Shs Float | 67.6M | Perf Month | -50.2% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.21 | Inst Own | 39.97% | Short Float | 23.25% | Perf Quarter | -47.34% |
| Income | -0.03B | P/S | - | EPS this Y | 37.63% | Inst Trans | 1.45% | Short Ratio | 7.59 | Perf Half Y | -58.01% |
| Sales | 0.00B | P/B | 3.84 | EPS next 5Y | 12.68% | ROA | -59.14% | Short Interest | 15.71M | Perf YTD | -48.19% |
| Book/sh | 0.17 | P/C | 1.32 | EPS past 3/5Y | 24.92% -46.26% | ROE | -164.14% | 52W High | -71.28% ($2.24) | Perf Year | -54.76% |
| Cash/sh | 0.49 | P/FCF | - | Sales past 3/5Y | - | ROIC | -268.09% | 52W Low | 16.33% ($0.55) | Perf 3Y | -94.14% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 83.55% | Gross Margin | - | Volatility(W/M) | 12.64% 10.95% | Perf 5Y | -94.27% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.12 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.47 | EPS Q/Q | 77.45% | Profit Margin | - | RSI (14) | 25.88 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.47 | Sales Q/Q | - | SMA20 | -37.15% ($1.02) | Beta | -0.22 | Target Price | $6.43 |
| Payout | - | Debt/Eq | 0.07 | Earnings | 2026/8/5 | SMA50 | -54.16% ($1.4) | Rel Volume | 0.63 | Prev Close | $0.64 |
| Employees | 41 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 46.31% - | SMA200 | -53.66% ($1.38) | Avg Volume(3M) | 2.07M | Price | $0.64 |
| IPO | 2021/4/16 | Option/Short | Yes/Yes | Trades | 2201 | Volume | 1,312,042 | Change | 1.07% |
🧬 Biomea Fusion (BMEA) is a US clinical-stage biotech company developing oral covalent small-molecule therapies. The company is building a pipeline centered on candidates that target metabolic diseases and genetically defined specific cancers, aiming to address areas of unmet medical need through a precision medicine approach. Progress in clinical development and regulatory milestones serve as key drivers of the company's value.
Over the past 1 year, on the lower side
71% below its 1-year high.
Traded less than usual. That is 63% of its average volume.
BMEA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +37.6% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.3%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
23.3% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #419 of 594 in the industry
Based on market cap of $47M.
IBIO#418 iBio Inc $47M PER - BMEA#419 Biomea Fusion Inc $47M PER - 
MREO#419 Mereo Biopharma Group Plc ADR $47M PER - 
HYPD#421 Hyperion DeFi Inc $46M PER - 
LONA#422 LeonaBio Inc $46M PER - 
FAQ
What kind of company is BMEA?
BMEA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BMEA?
The market cap of BMEA is approximately $47M, ranking 4,879 within its sector.
What is the 52-week high and low for BMEA?
BMEA has recorded a 52-week high of $2.24 and a low of $0.55.
